Contribution of whole-body MRI to the initial assessment of myxoid liposarcoma
CONCLUSION: The patients' young age, absence of reliable prognostic factors at diagnosis, asymptomatic nature of the lesions, and the benefits of early and targeted therapeutic management encourage the use of whole-body MRI as part of the initial work-up as it seems to provide a better initial staging compared with conventional imaging.PMID:37507239 | DOI:10.1016/j.bulcan.2023.05.009 (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - July 28, 2023 Category: Cancer & Oncology Authors: Julie Dewaguet Juliette Beaujot Cl émence Leguillette Gauthier Decanter Abel Cordoba Nicolas Penel Luc Ceugnart None SophieTaieb Mariem Ben Haj Amor Source Type: research
Creating a community of heads of department to meet hospital system challenges: First experience in haematology
Bull Cancer. 2023 Jul 26:S0007-4551(23)00298-9. doi: 10.1016/j.bulcan.2023.06.003. Online ahead of print.ABSTRACTThe French hospital system crises are constantly forcing the heads of departments to adapt and find solutions for maintaining optimal patient care in a context of staff shortage. Facing these challenges, we had the desire to create a community of department heads capable of helping each other, sharing their experiences, relying on collective intelligence and, ultimately, contributing to rebuilding their hospitals from the bottom up. In this respect, we arranged a two-day seminar, which brought together fourteen ...
Source: Bulletin du Cancer - July 28, 2023 Category: Cancer & Oncology Authors: Roch Houot Jacques-Olivier Bay Patrice Chevallier Sylvain Choquet Luc-Matthieu Fornecker Jean-Christophe Ianotto Arnaud Jaccard Fabrice Jardin Laurence Legros Fran çois Lemonnier Sophie Park Laurent Pascal Carole Soussain Emmanuel Gyan Source Type: research
De-escalation in aromatase inhibitors prescription for menopausal women with positive hormonal receptors breast cancer
Bull Cancer. 2023 Jul 26:S0007-4551(23)00301-6. doi: 10.1016/j.bulcan.2023.06.006. Online ahead of print.NO ABSTRACTPMID:37507238 | DOI:10.1016/j.bulcan.2023.06.006 (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - July 28, 2023 Category: Cancer & Oncology Authors: R émy J Salmon Source Type: research
Contribution of whole-body MRI to the initial assessment of myxoid liposarcoma
CONCLUSION: The patients' young age, absence of reliable prognostic factors at diagnosis, asymptomatic nature of the lesions, and the benefits of early and targeted therapeutic management encourage the use of whole-body MRI as part of the initial work-up as it seems to provide a better initial staging compared with conventional imaging.PMID:37507239 | DOI:10.1016/j.bulcan.2023.05.009 (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - July 28, 2023 Category: Cancer & Oncology Authors: Julie Dewaguet Juliette Beaujot Cl émence Leguillette Gauthier Decanter Abel Cordoba Nicolas Penel Luc Ceugnart None SophieTaieb Mariem Ben Haj Amor Source Type: research
Treatment of lower risk myelodysplastic syndromes
Bull Cancer. 2023 Jul 25:S0007-4551(23)00282-5. doi: 10.1016/j.bulcan.2023.02.027. Online ahead of print.ABSTRACTFor low-risk myelodysplastic syndromes, the goal of treatment is to correct cytopenias or their consequences. Erythropoiesis-stimulating agents have an important role in the management of anemia. In this chapter, we will detail the response to ESAs, the factors predictive of response to ESAs. However, the search for new therapeutic options for low-risk, ESA-resistant MDS remains necessary as the incidence of AML transformation of the patients is higher. We can retain luspatercept for MDS with excess ring of side...
Source: Bulletin du Cancer - July 27, 2023 Category: Cancer & Oncology Authors: Sophie Park Source Type: research
Cemiplimab in association to chemotherapy in advanced non-small cell lung cancer
Bull Cancer. 2023 Jul 25:S0007-4551(23)00292-8. doi: 10.1016/j.bulcan.2023.05.008. Online ahead of print.NO ABSTRACTPMID:37500386 | DOI:10.1016/j.bulcan.2023.05.008 (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - July 27, 2023 Category: Cancer & Oncology Authors: Adrien Rousseau Édouard Auclin Source Type: research
Futibatinib for cholangiocarcinomas with a FGFR2 fusion or rearrangement, locally advanced or metastatic
Bull Cancer. 2023 Jul 25:S0007-4551(23)00300-4. doi: 10.1016/j.bulcan.2023.06.005. Online ahead of print.NO ABSTRACTPMID:37500387 | DOI:10.1016/j.bulcan.2023.06.005 (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - July 27, 2023 Category: Cancer & Oncology Authors: Claire No é Julien Edeline Source Type: research
Vaccination of allogeneic haematopoietic stem cell transplant recipients: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)
Bull Cancer. 2023 Jul 19:S0007-4551(23)00289-8. doi: 10.1016/j.bulcan.2023.05.007. Online ahead of print.ABSTRACTDuring immune reconstitution following allogeneic haematopoietic stem cell transplantation (allo-HSCT), (re)vaccination of allo-HSCT recipients is recommended. Herein, we propose an update of practical recommendations regarding vaccination of allo-HSCT recipients. These recommendations, based on data from the literature, national and international guidelines and the consensus of the participants when no formally proven data are available, were elaborated during the workshop of practice harmonization organized by...
Source: Bulletin du Cancer - July 21, 2023 Category: Cancer & Oncology Authors: Anne Conrad Yves Beguin Sarah Guenounou Amandine Le Bourgeois Anne-Lise M énard Fanny Rialland Sharrouf Layal Anne-Claire Mamez Ibrahim Yakoub-Agha Jean El Cheikh Source Type: research
Vaccination of allogeneic haematopoietic stem cell transplant recipients: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)
Bull Cancer. 2023 Jul 19:S0007-4551(23)00289-8. doi: 10.1016/j.bulcan.2023.05.007. Online ahead of print.ABSTRACTDuring immune reconstitution following allogeneic haematopoietic stem cell transplantation (allo-HSCT), (re)vaccination of allo-HSCT recipients is recommended. Herein, we propose an update of practical recommendations regarding vaccination of allo-HSCT recipients. These recommendations, based on data from the literature, national and international guidelines and the consensus of the participants when no formally proven data are available, were elaborated during the workshop of practice harmonization organized by...
Source: Bulletin du Cancer - July 21, 2023 Category: Cancer & Oncology Authors: Anne Conrad Yves Beguin Sarah Guenounou Amandine Le Bourgeois Anne-Lise M énard Fanny Rialland Sharrouf Layal Anne-Claire Mamez Ibrahim Yakoub-Agha Jean El Cheikh Source Type: research
Vaccination of allogeneic haematopoietic stem cell transplant recipients: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)
Bull Cancer. 2023 Jul 19:S0007-4551(23)00289-8. doi: 10.1016/j.bulcan.2023.05.007. Online ahead of print.ABSTRACTDuring immune reconstitution following allogeneic haematopoietic stem cell transplantation (allo-HSCT), (re)vaccination of allo-HSCT recipients is recommended. Herein, we propose an update of practical recommendations regarding vaccination of allo-HSCT recipients. These recommendations, based on data from the literature, national and international guidelines and the consensus of the participants when no formally proven data are available, were elaborated during the workshop of practice harmonization organized by...
Source: Bulletin du Cancer - July 21, 2023 Category: Cancer & Oncology Authors: Anne Conrad Yves Beguin Sarah Guenounou Amandine Le Bourgeois Anne-Lise M énard Fanny Rialland Sharrouf Layal Anne-Claire Mamez Ibrahim Yakoub-Agha Jean El Cheikh Source Type: research
Vaccination of allogeneic haematopoietic stem cell transplant recipients: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)
Bull Cancer. 2023 Jul 19:S0007-4551(23)00289-8. doi: 10.1016/j.bulcan.2023.05.007. Online ahead of print.ABSTRACTDuring immune reconstitution following allogeneic haematopoietic stem cell transplantation (allo-HSCT), (re)vaccination of allo-HSCT recipients is recommended. Herein, we propose an update of practical recommendations regarding vaccination of allo-HSCT recipients. These recommendations, based on data from the literature, national and international guidelines and the consensus of the participants when no formally proven data are available, were elaborated during the workshop of practice harmonization organized by...
Source: Bulletin du Cancer - July 21, 2023 Category: Cancer & Oncology Authors: Anne Conrad Yves Beguin Sarah Guenounou Amandine Le Bourgeois Anne-Lise M énard Fanny Rialland Sharrouf Layal Anne-Claire Mamez Ibrahim Yakoub-Agha Jean El Cheikh Source Type: research
Vaccination of allogeneic haematopoietic stem cell transplant recipients: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)
Bull Cancer. 2023 Jul 19:S0007-4551(23)00289-8. doi: 10.1016/j.bulcan.2023.05.007. Online ahead of print.ABSTRACTDuring immune reconstitution following allogeneic haematopoietic stem cell transplantation (allo-HSCT), (re)vaccination of allo-HSCT recipients is recommended. Herein, we propose an update of practical recommendations regarding vaccination of allo-HSCT recipients. These recommendations, based on data from the literature, national and international guidelines and the consensus of the participants when no formally proven data are available, were elaborated during the workshop of practice harmonization organized by...
Source: Bulletin du Cancer - July 21, 2023 Category: Cancer & Oncology Authors: Anne Conrad Yves Beguin Sarah Guenounou Amandine Le Bourgeois Anne-Lise M énard Fanny Rialland Sharrouf Layal Anne-Claire Mamez Ibrahim Yakoub-Agha Jean El Cheikh Source Type: research
Venous thromboembolism and breast cancer
Bull Cancer. 2023 Jul 18:S0007-4551(23)00296-5. doi: 10.1016/j.bulcan.2023.06.001. Online ahead of print.ABSTRACTBreast cancer is the most common cancer in women. Patients with breast cancer have a 4-fold increased risk of venous thromboembolism (VTE) compared to age- and sex-matched controls without cancer. VTE remains the second leading cause of death in cancer patients and an independent risk factor for mortality. In women with breast cancer, the main risk factors for developing VTE are increasing age, obesity, disease stage, central catheter placement and cancer treatments, including surgery, chemotherapy, hormonothera...
Source: Bulletin du Cancer - July 20, 2023 Category: Cancer & Oncology Authors: Benjamin Crichi Emilie Moati Carlotta Cacciatore Dominique Farge Corinne Frere Source Type: research
Venous thromboembolism and breast cancer
Bull Cancer. 2023 Jul 18:S0007-4551(23)00296-5. doi: 10.1016/j.bulcan.2023.06.001. Online ahead of print.ABSTRACTBreast cancer is the most common cancer in women. Patients with breast cancer have a 4-fold increased risk of venous thromboembolism (VTE) compared to age- and sex-matched controls without cancer. VTE remains the second leading cause of death in cancer patients and an independent risk factor for mortality. In women with breast cancer, the main risk factors for developing VTE are increasing age, obesity, disease stage, central catheter placement and cancer treatments, including surgery, chemotherapy, hormonothera...
Source: Bulletin du Cancer - July 20, 2023 Category: Cancer & Oncology Authors: Benjamin Crichi Emilie Moati Carlotta Cacciatore Dominique Farge Corinne Frere Source Type: research
Breast density assessment and organised breast cancer screening
CONCLUSION: Our study showed moderate to good intra- and inter-raters agreements. Upgrading and harmonisation of practices will be used to empower radiologists to participate in organised breast cancer screening in Burkina Faso.PMID:37468338 | DOI:10.1016/j.bulcan.2023.05.010 (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - July 19, 2023 Category: Cancer & Oncology Authors: Augustin Tozoula Bambara Nina-Astrid Ou édraogo Pakisba Ali Ou édraogo Ouattara Lydia Bamis B énao Wilfried Ou édraogo L éon Gueswendé Blaise Savadogo Diallo Ouss éini Ciss é Rabiou Source Type: research
